A detailed history of Cetera Investment Advisers transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Cetera Investment Advisers holds 28,258 shares of AVXL stock, worth $102,859. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,258
Previous 15,822 78.6%
Holding current value
$102,859
Previous $145,000 73.1%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$8.44 - $13.41 $104,959 - $166,766
12,436 Added 78.6%
28,258 $251,000
Q2 2025

Aug 08, 2025

SELL
$7.37 - $9.63 $31,226 - $40,802
-4,237 Reduced 21.12%
15,822 $145,000
Q1 2025

May 06, 2025

BUY
$7.85 - $13.46 $47,555 - $81,540
6,058 Added 43.27%
20,059 $172,000
Q4 2024

Feb 13, 2025

BUY
$5.11 - $12.56 $71,545 - $175,852
14,001 New
14,001 $150,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $284M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.